ENDRA Life Sciences Inc. 8-K

What Happened

• ENDRA Life Sciences Inc. (NDRA) announced on March 25, 2026 that it has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. In connection with this revised strategy, the company reduced headcount on March 19, 2026 to lower cash expenditures and extend its operational runway.
• The company said it will continue to pursue its TAEUS business while it evaluates strategic options. A press release about the review was furnished as Exhibit 99.1 in the 8-K.

Key Details

• Date of announcement: March 25, 2026; workforce reduction occurred March 19, 2026.
• Expected pre-tax cash charge: approximately $51,000 related to severance payments to former employees.
• Timing: The company expects to recognize these severance charges in the first quarter of 2026.
• Purpose: Reduction and charges are tied to a revised strategy and efforts to extend the company’s operational runway.

Why It Matters

• The move signals management is actively pursuing ways to preserve cash and increase shareholder value, which can affect the company’s near-term cash burn and runway.
• The severance charge is relatively small ($51K) and will be recorded in Q1 2026, but the strategic review could lead to more significant actions or announcements in the future.
• Investors should monitor further SEC filings and company disclosures for details on the strategic alternatives and any material transactions or changes to operations.